What is Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development of pharmaceutically-produced transdermal cannabinoid therapies. Headquartered in Devon, Pennsylvania, the company focuses on addressing the unmet medical needs of patients suffering from rare and near-rare neuropsychiatric disorders. Its flagship product, Zygel, utilizes a permeation-enhanced gel for transdermal delivery, offering a novel therapeutic pathway for conditions that have historically lacked effective pharmacological interventions. Formerly known as AllTranz, Inc., the company rebranded in 2014 to better align with its strategic pivot toward cannabinoid-based medicine. By integrating advanced drug delivery technology with established pharmaceutical standards, Zynerba occupies a unique niche in the biotech ecosystem, bridging the gap between traditional neurology and innovative cannabinoid research.
How much funding has Zynerba Pharmaceuticals raised?
Zynerba Pharmaceuticals has raised a total of $149.2M across 4 funding rounds:
Unspecified
$13M
Stock Offering
$48.3M
Stock Offering
$58M
Stock Offering
$29.9M
Unspecified (2014): $13M with participation from Perceptive Advisors
Stock Issuance/Offering (2015): $48.3M led by Undisclosed
Stock Issuance/Offering (2017): $58M supported by Undisclosed
Stock Issuance/Offering (2018): $29.9M featuring Undisclosed
Key Investors in Zynerba Pharmaceuticals
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
Undisclosed Investors
Undisclosed Investors
What's next for Zynerba Pharmaceuticals?
Looking ahead, Zynerba Pharmaceuticals is positioned to leverage its recent capital influx to accelerate the clinical development of its transdermal pipeline. The strategic focus remains on achieving key regulatory milestones for Zygel, which is critical for validating the company's long-term commercial viability. As the firm transitions further into late-stage clinical trials, the emphasis will likely shift toward optimizing manufacturing scalability and preparing for potential market entry. Investors and stakeholders are closely monitoring the company's ability to translate its clinical data into tangible therapeutic outcomes, which will serve as the primary catalyst for future growth and potential strategic partnerships within the broader pharmaceutical industry.
See full Zynerba Pharmaceuticals company page
